SEC Tracker
Get the app

Oncocyte IMDX

Oncocyte Announces Initiatives to Focus Corporate Strategy

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract
Exhibit 10.3
Material contract
Exhibit 99.1
Press release
  • Signs a material agreement (1.01)
  • Announces exit or restructuring costs (2.05)
  • Reports an executive or board change (5.02)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Oncocyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Rein Therapeutics RNTX public float $32M, Jun 30, 2025
  2. Yarrow Bioscience VYNE public float $32M, Jun 30, 2025
  3. Kezar Life Sciences KZR public float $33M, Jun 30, 2025
  4. Scorpius Holdings SCPX
  5. Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025